H.R. 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025 (119th Congress) Bill Summary

This legislation, known as the Stem Cell Therapeutic and Research Reauthorization Act of 2025, aims to update and extend existing stem cell research and therapeutic programs. Below are the primary provisions included in the bill:

Reauthorization of Funding

The bill proposes to reauthorize the C.W. Bill Young Cell Transplantation Program, which involves:

Setting the annual funding appropriation at $33,009,000 for each fiscal year from 2027 through 2031.
Keeping the current funding level of $31,009,000 for the year 2026.

Extension of Cord Blood Inventory

The bill also includes a change to the timeline of the cord blood inventory, extending the expiration from 2026 to 2031. This indicates an ongoing commitment to maintaining and potentially expanding the collection and utilization of cord blood for therapeutic purposes.

The overall intent of this bill is to ensure continued support and funding for stem cell research and therapies, which have significant implications for medical treatments and advancements in healthcare.

Relevant Companies

None found

This is an AI-generated summary of the bill text. There may be mistakes.

Actions

7 actions

Date	Action
May. 21, 2026	Committee Consideration and Mark-up Session Held
May. 21, 2026	Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
May. 13, 2026	Forwarded by Subcommittee to Full Committee by Voice Vote.
May. 13, 2026	Subcommittee Consideration and Mark-up Session Held
Sep. 04, 2025	Introduced in House
Sep. 04, 2025	Referred to the House Committee on Energy and Commerce.
Sep. 04, 2025	Referred to the Subcommittee on Health.

Corporate Lobbying

0 companies lobbying

None found.

* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.

Potentially Relevant Congressional Stock Trades

No relevant congressional stock trades found.